Literature DB >> 30753095

Regulation and role of endoglin in cholesterol-induced endothelial and vascular dysfunction in vivo and in vitro.

Matej Vicen1, Barbora Vitverova1, Radim Havelek2, Katerina Blazickova1, Miloslav Machacek3, Jana Rathouska1, Iveta Najmanová1, Eva Dolezelova1, Alena Prasnicka1, Magdalena Sternak4, Carmelo Bernabeu5,6, Petr Nachtigal1.   

Abstract

Our objective was to investigate the effect of cholesterol [hypercholesterolemia and 7-ketocholesterol (7K)] on endoglin (Eng) expression and regulation with respect to endothelial or vascular dysfunction in vivo and in vitro. In vivo experiments were performed in 2-mo-old atherosclerosis-prone apolipoprotein E-deficient/LDL receptor-deficient (ApoE-/-/LDLR-/-) female mice and their wild-type C57BL/6J littermates. In in vitro experiments, human aortic endothelial cells (HAECs) were treated with 7K. ApoE-/-/LDLR-/- mice developed hypercholesterolemia accompanied by increased circulating levels of P-selectin and Eng and a disruption of NO metabolism. Functional analysis of the aorta demonstrated impaired vascular reactivity, and Western blot analysis revealed down-regulation of membrane Eng/Smad2/3/eNOS signaling in ApoE-/-/LDLR-/- mice. 7K increased Eng expression via Krüppel-like factor 6 (KLF6), liver X nuclear receptor, and NF-κB in HAECs. 7K-induced Eng expression was prevented by the treatment with 2-hydroxypropyl-β-cyclodextrin; 8-{[5-chloro-2-(4-methylpiperazin-1-yl) pyridine-4-carbonyl] amino}-1-(4-fluorophenyl)-4, 5-dihydrobenzo[g]indazole-3-carboxamide; or by KLF6 silencing. 7K induced increased adhesion and transmigration of monocytic human leukemia promonocytic cell line cells and was prevented by Eng silencing. We concluded that hypercholesterolemia altered Eng expression and signaling, followed by endothelial or vascular dysfunction before formation of atherosclerotic lesions in ApoE-/-/LDLR-/- mice. By contrast, 7K increased Eng expression and induced inflammation in HAECs, which was followed by an increased adhesion and transmigration of monocytes via endothelium, which was prevented by Eng inhibition. Thus, we propose a relevant role for Eng in endothelial or vascular dysfunction or inflammation when exposed to cholesterol.-Vicen, M., Vitverova, B., Havelek, R., Blazickova, K., Machacek, M., Rathouska, J., Najmanová, I., Dolezelova, E., Prasnicka, A., Sternak, M., Bernabeu, C., Nachtigal, P. Regulation and role of endoglin in cholesterol-induced endothelial and vascular dysfunction in vivo and in vitro.

Entities:  

Keywords:  endothelial cells; hypercholesterolemia; mice; oxysterols

Year:  2019        PMID: 30753095     DOI: 10.1096/fj.201802245R

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  12 in total

Review 1.  Membrane and soluble endoglin role in cardiovascular and metabolic disorders related to metabolic syndrome.

Authors:  Matej Vicen; Ivone Cristina Igreja Sá; Katarína Tripská; Barbora Vitverová; Iveta Najmanová; Samira Eissazadeh; Stanislav Micuda; Petr Nachtigal
Journal:  Cell Mol Life Sci       Date:  2020-11-13       Impact factor: 9.261

Review 2.  The role of endoglin and its soluble form in pathogenesis of preeclampsia.

Authors:  Georgia Margioula-Siarkou; Chrysoula Margioula-Siarkou; Stamatios Petousis; Kosmas Margaritis; Eleftherios Vavoulidis; Giuseppe Gullo; Maria Alexandratou; Konstantinos Dinas; Alexandros Sotiriadis; Georgios Mavromatidis
Journal:  Mol Cell Biochem       Date:  2021-11-16       Impact factor: 3.396

3.  Potential Role of Circulating Endoglin in Hypertension via the Upregulated Expression of BMP4.

Authors:  Eunate Gallardo-Vara; Luis Gamella-Pozuelo; Lucía Perez-Roque; José L Bartha; Irene Garcia-Palmero; J Ignacio Casal; José M López-Novoa; Miguel Pericacho; Carmelo Bernabeu
Journal:  Cells       Date:  2020-04-16       Impact factor: 6.600

4.  Effect of Ergothioneine on 7-Ketocholesterol-Induced Endothelial Injury.

Authors:  Sally Shuxian Koh; Samantha Chia-Yi Ooi; Natalie Man-Yin Lui; Cao Qiong; Leona Ting-Yuke Ho; Irwin Kee-Mun Cheah; Barry Halliwell; Deron R Herr; Wei-Yi Ong
Journal:  Neuromolecular Med       Date:  2020-10-16       Impact factor: 3.843

5.  Soluble Endoglin as a Potential Biomarker of Nonalcoholic Steatohepatitis (NASH) Development, Participating in Aggravation of NASH-Related Changes in Mouse Liver.

Authors:  Ivone Cristina Igreja Sá; Katarina Tripska; Milos Hroch; Radomir Hyspler; Alena Ticha; Hana Lastuvkova; Jolana Schreiberova; Eva Dolezelova; Samira Eissazadeh; Barbora Vitverova; Iveta Najmanova; Martina Vasinova; Miguel Pericacho; Stanislav Micuda; Petr Nachtigal
Journal:  Int J Mol Sci       Date:  2020-11-27       Impact factor: 5.923

6.  Monitoring of up to 15 years effects of lipoprotein apheresis on lipids, biomarkers of inflammation, and soluble endoglin in familial hypercholesterolemia patients.

Authors:  J Víšek; M Bláha; V Bláha; M Lášticová; M Lánska; C Andrýs; J Duintjer Tebbens; Ivone Cristina Igreja E Sá; K Tripská; M Vicen; I Najmanová; P Nachtigal
Journal:  Orphanet J Rare Dis       Date:  2021-02-27       Impact factor: 4.123

7.  Sitagliptin protects renal glomerular endothelial cells against high glucose-induced dysfunction and injury.

Authors:  Liang Xu; Fengmin Shao
Journal:  Bioengineered       Date:  2022-01       Impact factor: 3.269

8.  Endoglin Protein Interactome Profiling Identifies TRIM21 and Galectin-3 as New Binding Partners.

Authors:  Eunate Gallardo-Vara; Lidia Ruiz-Llorente; Juan Casado-Vela; María J Ruiz-Rodríguez; Natalia López-Andrés; Asit K Pattnaik; Miguel Quintanilla; Carmelo Bernabeu
Journal:  Cells       Date:  2019-09-13       Impact factor: 6.600

9.  Apremilast ameliorates ox-LDL-induced endothelial dysfunction mediated by KLF6.

Authors:  Hao Wang; Guang Yang; Qian Zhang; Xiao Liang; Yang Liu; Meng Gao; Yutao Guo; Li Chen
Journal:  Aging (Albany NY)       Date:  2020-10-14       Impact factor: 5.682

10.  High Soluble Endoglin Levels Affect Aortic Vascular Function during Mice Aging.

Authors:  Iveta Nejmanová; Barbora Vitverová; Samira Eissazadeh; Katarina Tripská; Ivone Cristina Igreja Sa; Radomír Hyšpler; Ivana Němečkova; Miguel Pericacho; Petr Nachtigal
Journal:  J Cardiovasc Dev Dis       Date:  2021-12-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.